CSCI (cosciensbio.com) Earnings per share growth this year

Official company branding of COSCIENS Bio (CSCI)

COSCIENS Biopharma Inc. (CSCI) attracts scientists with academic freedom and stock options, as evidenced by the distribution of annual earnings per share changes. The value of 0.00 indicates the current yield level. Capital is generated through the exclusive distribution of orphan drugs in Latin America and Canada. Isolation from global macroeconomic fluctuations transforms the company into a resilient defensive asset with constant demand.

CSCI (cosciensbio.com) Earnings per share growth in current year history from 08/10/2024 to 09/14/2025

Financial and market metric breakdowns for COSCIENS Biopharma Inc. (CSCI)

- stock value and consensus price forecast:
Market Price COSCIENS Biopharma Inc|CSCI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization COSCIENS Bio|CSCI - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value of a Share COSCIENS Biopharma|CSCI - Company Book Value|Market Capitalization to Net Assets cosciensbio.com|CSCI - Company Total Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Capital|Short-Term Debt to Capital cosciensbio.com|CSCI - Company Debts|Debt to Net Assets Ratio COSCIENS Bio|CSCI - Company Long-Term Debt|Company Current Liabilities COSCIENS Biopharma|Quick Ratio cosciensbio.com
- net income and valuation multiples indicators:
CSCI - Net Profit|Future Profit COSCIENS Biopharma Inc.|CSCI - Price to Earnings Ratio|Projected Price to Earnings Ratio COSCIENS Bio|CSCI - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio COSCIENS Bio|CSCI - Operating profit EBITDA|Net earnings per share for the last 12 months COSCIENS Biopharma|CSCI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months cosciensbio.com|CSCI - Earnings growth in current year|Expected net earnings per share growth next year COSCIENS Biopharma Inc.
Basic company analysis:COSCIENS Biopharma Inc (CSCI)
Manufactured products of COSCIENS Biopharma Inc.

When selecting defensive assets, high market resilience and the possession of patents are the priorities. COSCIENS Biopharma Inc. (CSCI) ensures this stability through its exclusive drug Macrilen for the diagnosis of endocrine pathologies. The year-over-year EPS trend reflects the percentage shift in net income per share, allowing for a real-time assessment of the business's capitalization efficiency relative to the previous year.

Main competitors

Earnings per share growth rate in current year Vertex Pharmaceuticals Incorporated (VRTX)|ALNY (Alnylam Inc.) - Earnings growth in current year|Earnings per share growth this year INSM (Insmed Corp)|Net earnings per share growth this year UTHR (United Therapeutics)|BMRN (biomarin.com) - Earnings per share increase in current year|Earnings per share growth in current year BridgeBio BBIO|BGM (BGM Group Limited) - Earnings per share trend in current year|Cogent Bio - Earnings growth in current year|Earnings per share increase in current year XERS (Xeris Pharma)|KROS: Earnings growth in current year|arcturusrx.com (ARCT) - Earnings growth in current year|Earnings per share growth in current year Eton Pharmaceuticals, Inc.|KMDA: Earnings per share increase in current year|Earnings per share growth in current year Fulcrum Tx (FULC)|Net earnings per share growth this year abeonatherapeutics.com ABEO|Earnings growth in current year MREO (Mereo BioPharma Group plc)|Earnings growth in current year protalix.com PLX|Pliant Rx - Earnings growth in current year|appliedtherapeutics.com (APLT) - Net earnings per share growth this year|Rein Therapeutics, Inc. (RNTX) - Earnings per share growth in current year|Earnings per share growth rate in current year Gelteq (GELS)|Earnings per share growth in current year Aytu BioPharma Inc|Chemomab (CMMB) - Expected net earnings per share growth this year|Earnings growth in current year SRXH|Net earnings per share growth this year polyrizon-biotech.com PLRZ|Earnings growth in current year AEZS (Aeterna Zentaris Inc.)|Expected net earnings per share growth this year Cyclo Therapeutics, Inc (CYTH)|Inozyme - Earnings growth in current year|Earnings per share growth rate in current year reneopharma.com